| abstract |
Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment of various cancers. Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen. |